Compare AEF & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AEF | EBS |
|---|---|---|
| Founded | 1989 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 338.2M | 303.3M |
| IPO Year | N/A | 2006 |
| Metric | AEF | EBS |
|---|---|---|
| Price | $7.22 | $5.16 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 104.9K | ★ 917.9K |
| Earning Date | 01-01-0001 | 11-02-2026 |
| Dividend Yield | ★ 7.13% | N/A |
| EPS Growth | N/A | ★ 125.83 |
| EPS | ★ 0.57 | N/A |
| Revenue | N/A | ★ $742,900,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.03 |
| P/E Ratio | $13.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.41 | $4.36 |
| 52 Week High | $10.14 | $14.06 |
| Indicator | AEF | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 28.82 | 28.53 |
| Support Level | $6.88 | $4.36 |
| Resistance Level | $10.07 | $7.18 |
| Average True Range (ATR) | 0.23 | 0.44 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 1.94 | 5.06 |
ABERDEEN EMERGING MARKETS EQUITY INCOME FUND, INC. is a non-diversified closed-end, management investment company. Its investment objective is to seek to provide both current income and long-term capital appreciation. Under normal circumstances, the fund invests a majority of its net assets (plus any borrowings for investment purposes) in emerging markets (excluding China) equity securities. The performance of the fund is measured against the MSCI Emerging Markets ex-China Index. Its investment portfolio consists of equity securities from emerging market companies (excluding China), spanning multiple sectors such as Information Technology, Financials, Industrials, Consumer Discretionary, Real Estate, and others.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.